How an EMA Safety Referral Starts: From Safety Concern to Formal EU Procedure

Introduction

An EU safety referral does not normally begin with the publication of an EMA referral page. By the time a formal referral is announced, a safety concern has already passed through one or more stages of pharmacovigilance assessment and regulatory consideration.

Understanding that preceding pathway is important for anyone working in pharmacovigilance or regulatory affairs. A referral is a formal legal procedure, whereas a safety signal is a pharmacovigilance finding that may or may not ultimately require such a procedure. Most safety signals do not become referrals. A referral becomes relevant when the available information and the applicable legal framework indicate that the matter requires a Union-level regulatory assessment or urgent Union action.

The progression can therefore be represented as:

New safety information
        ↓
Routine pharmacovigilance assessment
        ↓
Potential safety signal or emerging concern
        ↓
Medical and regulatory evaluation
        ↓
Assessment of whether routine measures are sufficient
        ↓
Consideration of Union-level action
        ↓
Selection of the applicable legal mechanism
        ↓
Formal referral notification
        ↓
PRAC / CHMP assessment according to the procedure

This is a conceptual model rather than a statutory step-by-step sequence. The route can vary according to the source of the concern, the products involved, the authorisation route, the urgency and the legal basis.

The key principle is:

A safety concern is not itself an EMA referral. A referral is a formal regulatory procedure that begins when the competent Union procedure is initiated under its applicable legal framework.

This article explains the transition between those two states.

1. Safety Surveillance Comes Before the Referral

Medicinal products remain under pharmacovigilance surveillance after authorisation. Safety information can arise from many sources, including spontaneous reports, clinical studies, literature, epidemiological studies, post-authorisation safety studies, medication-error information, reports from patients or healthcare professionals, and other sources of safety-relevant evidence.

The appearance of new information does not automatically mean that a regulatory action is required.

The initial task is to determine what the information means.

A report of an adverse event may be isolated, already expected, confounded by the underlying disease, or consistent with the established safety profile. Conversely, apparently limited information may become important when considered with other evidence or when it identifies a previously unrecognised pattern.

Pharmacovigilance therefore operates through evaluation rather than simple counting.

The relevant question is not merely:

“How many reports have been received?”

It is:

“Does the totality of available evidence indicate a new, changed or insufficiently characterised risk that requires further evaluation or action?”

That distinction is fundamental to understanding how a referral can arise.

2. From Safety Information to a Safety Signal

A safety signal is a type of information that warrants further investigation because it suggests a new potentially causal association, or a new aspect of a known association, between a medicinal product and an event.

A signal is therefore a hypothesis-generating pharmacovigilance finding, not a confirmed causal conclusion.

The signal-management process evaluates the available evidence and determines whether further analysis is warranted. The evidence may include individual case safety reports, aggregate data, exposure information, literature, clinical-trial evidence, epidemiological studies, biological plausibility and information concerning alternative explanations.

This distinction is particularly important when considering escalation to a referral.

A signal can have several possible outcomes:

• the signal may be refuted;
• the signal may remain under monitoring;
• additional information may be requested;
• the product's safety profile may be updated;
• routine risk-minimisation may be strengthened;
• an RMP or post-authorisation study may require modification;
• a variation may become appropriate; or
• a Union referral may be required.

A referral is therefore one possible regulatory consequence of a safety concern, not the default destination of every signal.

3. When Does a Safety Concern Become a Regulatory Issue?

The transition from pharmacovigilance assessment to regulatory action occurs when the evidence and circumstances indicate that the authorised conditions of use, risk-management measures or regulatory status of the medicine may need to change.

Examples of questions that can trigger this consideration include:

• Is there evidence of a new serious risk?
• Has the frequency or severity of a known risk changed materially?
• Is a particular population at greater risk than previously understood?
• Is the current product information adequate?
• Are existing risk-minimisation measures sufficient?
• Is there uncertainty that requires additional regulatory action?
• Does the benefit-risk balance remain favourable under the current conditions of use?
• Does the issue affect more than one nationally authorised product or Member State?
• Is urgent regulatory action being considered?

These questions do not themselves constitute legal thresholds. They are the types of regulatory questions that help determine whether the issue can be managed through existing mechanisms or requires escalation.

The actual legal trigger must come from the applicable legislation and procedure.

4. Routine Pharmacovigilance Measures Versus a Union Referral

A useful distinction is between managing a safety issue within the existing pharmacovigilance framework and bringing the issue into a formal Union referral procedure.

Routine or less escalated measures can include activities such as continued signal monitoring, additional analysis, requests for information, updates to safety documentation, changes to the risk-management system or a variation to the marketing authorisation where the applicable procedure permits.

A referral becomes relevant when the issue requires a formal Union-level assessment or action under a referral provision.

EMA describes referrals as procedures used to resolve issues such as concerns over the safety or benefits of a medicine or class of medicines, with the matter referred to the Agency so that a harmonised Union position can be established. Safety-related referrals are assessed by PRAC and subsequently, depending on the products concerned, by CHMP or CMDh. citeturn0search0

The important conceptual distinction is therefore:

5. Who Can Bring a Safety Issue to the Union Level?

The initiating authority depends on the legal basis.

EMA's referral framework states generally that referrals can be started by the European Commission, a Member State or the company that markets the medicine, although the specific legal basis determines who can formally initiate a particular procedure. citeturn0search0

This qualification is essential.

For example:

• an Article 20 pharmacovigilance procedure can only be initiated by the European Commission;
• an Article 31 pharmacovigilance referral can be initiated by a Member State competent authority, the European Commission or an MAH, subject to the legal framework;
• an Article 107i urgent Union procedure can be initiated by a Member State or the European Commission.

The MAH therefore does not have a universal right to choose the referral mechanism.

Even where an MAH can initiate an Article 31 pharmacovigilance referral, the formal notification and scope of the Union question remain governed by the applicable procedure. EMA specifically states that, for Article 31 pharmacovigilance referrals, only the Member State concerned or the Commission can identify the question referred to PRAC; an MAH seeking a referral should therefore engage with a Member State or the Commission to establish the Union interest and the appropriate question. citeturn0search4

6. The First Major Decision: Is Union-Level Action Necessary?

Before selecting Article 20, Article 31 or Article 107i, the underlying regulatory question is whether the matter requires a Union procedure at all.

A safety concern may remain within existing national or company pharmacovigilance processes when the available evidence can be appropriately managed through those mechanisms.

Union-level consideration becomes particularly important where the issue crosses national or authorisation boundaries, where a common regulatory position is required, or where the legal criteria for an urgent Union procedure are met.

This is why the authorisation status of the affected products must be established early.

For example, an issue involving only centrally authorised products follows a different pharmacovigilance route from one affecting both centrally and nationally authorised products. EMA's current Article 20 guidance states that an Article 20 pharmacovigilance procedure applies to centrally authorised products only; where the safety concern involves nationally authorised products as well, Article 31 or Article 107i is used as appropriate. citeturn0search1

The decision is therefore not simply:

“Is this safety issue serious enough for EMA?”

It is a more structured question:

“What regulatory problem exists, which products are affected, and does the applicable legislation require or permit a Union procedure?”

7. The Second Major Decision: Which Legal Route?

Once Union-level action is being considered, the legal route must be identified.

Article 20 pharmacovigilance

Article 20 of Regulation (EC) No 726/2004 is the pharmacovigilance route for centrally authorised medicinal products. EMA states that it applies when a Member State or the Commission, following evaluation of pharmacovigilance data, considers that a measure under the pharmacovigilance or supervision provisions of Directive 2001/83/EC should be applied to centrally authorised products. Only the Commission can formally initiate the procedure. citeturn0search1

Article 31 pharmacovigilance

Article 31 is used where the interests of the Union are involved following evaluation of pharmacovigilance data and none of the Article 107i criteria apply. It can cover nationally authorised and centrally authorised products within the defined scope. citeturn0search4

Article 107i

Article 107i is the urgent Union procedure. It applies when the statutory circumstances for urgent regulatory action following a pharmacovigilance concern are met. These include specified situations involving suspension or revocation, prohibition of supply, refusal of renewal, and certain major changes such as a new contraindication, dose reduction or restriction of indications where the legislative conditions are satisfied. citeturn0search0

The distinction is important because “urgent” is not a synonym for “serious.” The legal criteria determine whether Article 107i applies.

8. The Authorisation Route Matters

The same active substance can exist in the EU under different authorisation routes.

For example, a hypothetical active substance might have:

If a safety issue affects only Product A, the Article 20 pharmacovigilance pathway may be applicable.

If the issue affects Products A–D, the broader scope may require Article 31 or Article 107i, depending on the legal circumstances.

This is why a pharmacovigilance assessment should not stop at the company product database. The regulatory team needs to understand the EU authorisation landscape for the active substance or class concerned.

The question is not merely “which products do we own?” It is “which authorised products are within the regulatory scope of the safety concern?”

9. Urgency Is a Separate Regulatory Dimension

A safety concern can be scientifically important without meeting the legal criteria for an urgent Union procedure.

Conversely, a situation may require urgent regulatory action even while the evidence remains subject to detailed scientific evaluation.

Article 107i exists because the regulatory system needs a mechanism for circumstances in which urgent action is being considered. EMA maintains a separate procedural timetable for Article 107i urgent Union procedures, distinct from the timetable used for Article 20 and Article 31 pharmacovigilance referrals. The current EMA timetable documents were updated in June 2026. citeturn0search2

This distinction has practical implications for the MAH.

When an urgent procedure is initiated, the organisation must be able to mobilise rapidly without treating urgency as permission to lower the scientific standard of the response.

The operational challenge is therefore:

rapid mobilisation without loss of evidentiary discipline.

10. The Formal Notification Changes the Nature of the Work

The transition from an emerging safety concern to a formal referral is marked by the initiation of the legal procedure and the circulation of a formal notification.

For an Article 20 pharmacovigilance procedure, EMA states that the European Commission's notification identifies the safety concern, provides a detailed explanation of the issue and identifies the need for regulatory action to be considered. citeturn0search1

For an Article 31 pharmacovigilance referral, the notification identifies the safety concern and the question(s) referred to PRAC, explains the issue and addresses how the interests of the Union are involved. citeturn0search4

The notification is therefore more than an announcement.

It establishes the formal regulatory frame for the assessment.

Once the referral has started, the MAH should not assume that the entire historical safety dossier is equally relevant. The organisation needs to identify:

• the exact question referred;
• the products within scope;
• the relevant time period;
• the evidence requested or required;
• the regulatory action under consideration;
• the applicable timetable;
• the submission mechanism; and
• the internal governance needed to produce a coherent response.

11. Publication of the Referral Does Not Mean the Outcome Is Known

A common misunderstanding is to read the publication of a referral as evidence that a particular regulatory conclusion has already been reached.

That is incorrect.

The initiation of a referral means that the issue has entered the formal assessment process. The scientific conclusion still has to be developed through the procedure.

EMA publishes information on the start of safety-related referrals and subsequently publishes information on PRAC recommendations and final conclusions. citeturn0search0turn0search24

The distinction can be expressed simply:

Referral initiated
       ≠
Safety risk confirmed
       ≠
Regulatory action decided

A referral is an assessment mechanism. Its outcome depends on the evidence considered and the applicable regulatory framework.

12. What Happens Immediately After Initiation?

Once the formal referral has started, the procedure moves into its defined assessment phase.

For safety-related referrals, PRAC is the principal scientific committee for the pharmacovigilance assessment. EMA's referral framework states that safety-related referrals are assessed by PRAC and subsequently by CHMP or CMDh depending on the products involved. citeturn0search0

The procedure then becomes a structured regulatory assessment rather than an open-ended signal-management exercise.

The MAH must work from the formal questions and timetable, identify the evidence relevant to those questions, and submit the response through the applicable EMA submission mechanism.

EMA maintains specific referral guidance covering dossier requirements, submission mechanisms and procedural timetables. Current guidance identifies separate timetables for Article 20/31 pharmacovigilance referrals and Article 107i urgent Union procedures. citeturn0search3turn0search2

The next article in this series will examine what happens inside that assessment phase: how PRAC analyses the safety issue, how evidence is weighed, how rapporteur assessment works, and how a pharmacovigilance concern is translated into a regulatory recommendation.

13. A Useful Mental Model

For working pharmacovigilance professionals, the entire transition can be reduced to six questions:

1. What new information has emerged?
2. What does the totality of evidence suggest?
3. Does the issue require regulatory action?
4. Does it require Union-level action?
5. Which legal mechanism applies?
6. What exactly has been referred for assessment?

The sixth question is often the most important once the procedure has formally started.

A referral is not simply “about the drug” or “about the adverse event”. It is about the specific regulatory question defined by the procedure.

That distinction will become central when reading PRAC assessment reports and recommendations.

14. From Initiating Notification to a Defined Procedure

Once the referral has been formally initiated, the regulatory work becomes more structured. The initiating notification establishes the legal basis and the regulatory question, while the associated public and procedural documents define the practical scope of the assessment.

For the MAH, this is the point at which a potentially developing safety issue becomes a formal regulatory project.

The organisation should establish, at minimum:

• the legal basis of the procedure;
• the date on which the procedure was initiated;
• the products and marketing authorisations within scope;
• the active substance or substances concerned;
• the formal safety concern;
• the questions referred for assessment;
• the regulatory action being considered;
• the applicable submission timetable;
• the relevant EMA procedure lead and communication route; and
• the internal accountable functions and governance arrangements.

These elements should be captured in a controlled regulatory record. A referral should not be managed solely through email correspondence or through an informal project tracker because the regulatory history may later need to be reconstructed for inspection, audit, legal review or subsequent pharmacovigilance assessment.

EMA's referral guidance provides procedure-specific information on dossier requirements, submission mechanisms and timetables. The Agency maintains separate timetables for Article 20/Article 31 pharmacovigilance referrals and Article 107i urgent Union procedures. citeturn0search1turn0search0

15. The Scope of the Referral Must Be Read, Not Assumed

One of the most important tasks after initiation is to determine exactly what is within scope.

A referral may concern:

• one medicinal product;
• several products containing the same active substance;
• products containing different active substances within a therapeutic class; or
• a defined subset of products affected by the regulatory concern.

The existence of a common active substance does not, by itself, answer the scope question. Nor does the fact that another company has been named in the initial safety concern.

The formal procedure documents determine which products are actually being assessed.

This is particularly important for an MAH with a large European portfolio. A company may hold:

• centrally authorised products;
• products authorised nationally;
• products authorised through MRP;
• products authorised through DCP; and
• products that have different regulatory histories in different Member States.

The regulatory team must map those authorisations against the published scope.

For Article 20 pharmacovigilance, EMA explicitly limits the procedure to centrally authorised medicinal products. Where a safety concern extends to nationally authorised medicines as well, Article 31 pharmacovigilance or Article 107i may apply according to the circumstances. citeturn0search2

For Article 107i, the scope can encompass affected medicinal products with valid marketing authorisations in the EEA, including centrally and nationally authorised products, subject to the applicable legal criteria and procedure. citeturn0search6

The practical rule is simple:

Do not infer the scope from the active substance. Read the formal product list and the initiating notification.

16. The Questions Referred to the Committee

The formal questions are the centre of the scientific assessment.

A referral is not an unrestricted review of everything known about a medicine. The committee is asked to answer defined regulatory questions within the legal scope of the procedure.

Those questions may concern matters such as:

• whether the available evidence supports a causal association;
• the clinical significance of the risk;
• the frequency or severity of the event;
• affected populations;
• risk factors;
• the balance between benefit and risk;
• whether existing warnings are adequate;
• whether contraindications or restrictions are warranted;
• whether additional risk-minimisation measures are required; or
• whether more substantial regulatory action should be considered.

The precise questions depend on the procedure.

A good MAH response therefore begins by converting the formal questions into an evidence map.

For example:

The table is an internal working tool, not a regulatory requirement. Its value is that it prevents the response from becoming a collection of disconnected analyses.

17. The MAH's Evidence Package

Once a referral begins, the MAH must rapidly establish a reliable evidence base.

The appropriate evidence depends on the referral question, but a pharmacovigilance response may require integration of:

• individual case safety reports;
• cumulative case-series analysis;
• exposure estimates;
• signal-detection history;
• literature evidence;
• clinical-trial data;
• epidemiological studies;
• post-authorisation safety studies;
• mechanistic or biological evidence;
• relevant non-clinical evidence;
• previous regulatory assessments;
• previous variations and safety communications;
• risk-management measures and their effectiveness; and
• relevant benefit information.

The evidence should be traceable to its source and analysis method.

A referral response should also distinguish three different categories of statement:

1. Observed evidence — what the data actually show.
2. Scientific interpretation — what those observations may mean.
3. Regulatory conclusion — what action is justified in light of the evidence and the applicable legal framework.

Confusing these levels is a common source of weak regulatory arguments.

For example, an increased reporting frequency is an observation. It is not, by itself, proof of increased incidence or causality. A proposed mechanism may support biological plausibility, but plausibility is not equivalent to clinical confirmation. A regulatory conclusion must integrate the evidence rather than rest on one attractive finding.

18. Signal History Becomes Regulatory History

A formal referral often requires the MAH to reconstruct the development of the safety issue.

The chronology may include:

First relevant observation
        ↓
Signal detection
        ↓
Initial validation / evaluation
        ↓
Additional evidence
        ↓
Internal safety assessment
        ↓
Previous regulatory action, if any
        ↓
Emerging concern
        ↓
Referral initiation

The purpose is not to create a narrative merely for completeness. The chronology helps the committee understand what was known at each point, what action was taken, and how the evidence evolved.

This is particularly important when the referral concerns a known risk whose frequency, severity, population affected or clinical consequences may have changed.

The MAH should therefore be able to answer:

• When was the issue first identified?
• When was it first recognised as a potential signal?
• What evidence was available at each major assessment point?
• What conclusions were reached?
• What actions were taken?
• What new evidence changed the assessment?
• Why did the issue ultimately require Union-level consideration?

This chronology can become highly relevant during an inspection because it connects the pharmacovigilance system's historical decisions with the regulatory event.

19. The Role of the QPPV Before and During Initiation

The QPPV's role should not be reduced to signing off the final response.

Where a potential safety issue could plausibly develop into a major regulatory procedure, the QPPV should have sufficient visibility of the issue and its evaluation to understand the implications for the pharmacovigilance system.

The QPPV should be able to determine whether the organisation has:

• identified the relevant safety issue appropriately;
• evaluated the available evidence through the established pharmacovigilance system;
• escalated material concerns through appropriate governance;
• maintained adequate records of the assessments and decisions;
• identified relevant products and authorisations;
• coordinated the pharmacovigilance and regulatory response;
• considered implications for the RMP and other safety activities; and
• retained an auditable record of the reasoning supporting major decisions.

This does not mean that every referral decision is made by the QPPV personally. Regulatory responsibilities remain distributed according to the organisation's governance model and applicable legal obligations.

The QPPV's significance is that the referral should remain connected to the pharmacovigilance system rather than becoming an isolated regulatory exercise.

20. Mobilising the Organisation After Referral Initiation

A referral can expose weaknesses that are not obvious during routine pharmacovigilance.

The company may suddenly need to reconcile information held by different functions, systems and historical teams.

A robust mobilisation process should establish:

20.1 One controlled regulatory question set

The organisation should work from the formal referral questions rather than from multiple internally modified versions.

20.2 One evidence inventory

The team should know what evidence exists, where it is held, who owns it and whether it has already been assessed.

20.3 One agreed scientific position

Different departments should not submit inconsistent interpretations of the same evidence.

20.4 Clear document ownership

Every major section of the response should have an identified scientific or regulatory owner and an appropriate review process.

20.5 Traceable decision-making

Important judgements should have documented rationale, especially where evidence is uncertain or competing interpretations exist.

20.6 Controlled submission

The final response should be version-controlled and submitted through the applicable EMA mechanism within the published timetable.

EMA's referral guidance identifies the eSubmission Gateway/Web Client and related submission infrastructure for referral procedures, with IRIS used for relevant product-related regulatory communications and procedures. citeturn0search1

The exact submission route depends on the procedure and current EMA requirements and should therefore be checked against the procedure-specific guidance rather than assumed from a previous referral.

21. The Procedural Timetable Is a Regulatory Control

A referral timetable is not merely an administrative calendar.

It establishes when the different stages of the procedure are expected to occur and therefore determines when the MAH must be capable of producing evidence, responses and supporting documents.

EMA currently publishes a specific timetable for Article 20 and Article 31 pharmacovigilance safety referrals and a separate timetable for Article 107i urgent Union procedures. Both were updated on 4 June 2026. citeturn0search0

The existence of separate timetables reflects a substantive procedural difference rather than a cosmetic administrative distinction.

For an urgent Union procedure, the shorter regulatory window can materially change the internal operating model. Data extraction, medical review, statistical analysis, regulatory drafting and senior governance may have to proceed in parallel.

For a non-urgent referral, the timetable may permit more staged development, but the MAH should not interpret the additional time as permission to delay evidence assembly.

A referral timetable should therefore be incorporated into the company's controlled project plan as soon as the procedure begins.

22. What EMA Publishes at the Start

Transparency is an important feature of the Union referral system.

EMA's publication framework identifies information that can become publicly available when an Article 20, Article 31 or Article 107i referral begins. This can include the announcement, notification, draft product list, list of questions and timetable; for Article 107i procedures, the rationale for the urgent procedure and stakeholder questions can also be published. citeturn0search8

This means that the MAH should monitor the public procedure page as well as its direct regulatory communications.

The published page can evolve during the procedure. EMA's referral guidance advises MAHs to follow the relevant procedure information and updates. citeturn0search1

A useful operational distinction is:

The company's internal project record is the authoritative record of the company's decisions and actions; the EMA procedure page is the authoritative public record of the Union procedure and its published documents.

The two records should be reconciled throughout the procedure.

23. A Referral Is Not a Negotiation Between the MAH and EMA

The MAH participates in the scientific assessment, but the procedure is not a conventional negotiation in which the company and Agency bargain over an agreed outcome.

The committee evaluates the evidence within its legal mandate.

The MAH's role is to provide accurate, complete and scientifically reasoned information, respond to the questions, identify relevant uncertainties and explain the consequences of possible regulatory options.

This distinction matters when preparing regulatory strategy.

A response should not be designed merely to defend the existing label. It should demonstrate that the company has evaluated the evidence objectively and has considered the available regulatory options.

Where the evidence supports a change, attempting to minimise the issue through selective presentation can damage credibility. Where the evidence does not support a proposed regulatory restriction, the response should explain why using transparent evidence and explicit reasoning.

The strongest referral responses are therefore not necessarily those that argue most aggressively for a predetermined outcome. They are those that make the evidence, uncertainty and regulatory implications easiest for the committee to evaluate.

24. What Does Not Automatically Happen When a Referral Starts?

Several assumptions should be avoided.

A referral does not automatically mean the medicine will be withdrawn

A referral is an assessment procedure. The eventual regulatory action depends on the scientific assessment and legal framework.

A referral does not automatically confirm causality

The safety concern is the subject of assessment. The referral announcement is not a causal conclusion.

A referral does not automatically mean every product containing the active substance is included

The formal scope must be checked.

A referral does not automatically mean the same regulatory action will apply to every product

The outcome depends on the products, evidence, authorisation routes and applicable legal framework.

A referral does not replace routine pharmacovigilance

The MAH remains responsible for its ongoing pharmacovigilance activities while the referral is underway.

A referral does not end when PRAC adopts its recommendation

Depending on the legal basis and products involved, further committee and Union decision-making steps follow, together with implementation and subsequent pharmacovigilance activity.

These distinctions are important because referral announcements are sometimes interpreted as if they were regulatory decisions rather than the beginning of a formal assessment.

25. A Worked Example: From Signal to Referral

Consider a hypothetical medicinal product containing Active Substance X.

Routine pharmacovigilance identifies a cluster of serious hepatic events. Initial case review identifies several plausible alternative explanations, but additional cases accumulate and the pattern becomes sufficiently concerning to warrant a broader assessment.

The MAH performs signal evaluation and integrates:

• individual cases;
• exposure estimates;
• literature;
• clinical-trial information;
• epidemiological evidence;
• potential risk factors; and
• previous regulatory knowledge.

The evidence suggests that the issue may represent a clinically important risk requiring regulatory consideration.

At this point, several things have not yet been established:

• the final causal conclusion;
• the final frequency of the risk;
• the appropriate regulatory measure;
• whether a referral is legally required;
• which products should be included; or
• whether the benefit-risk balance remains favourable under all circumstances.

Those questions are precisely why further regulatory assessment may be required.

Suppose the concern involves only centrally authorised products. The Article 20 pharmacovigilance pathway may be relevant.

Suppose instead that the concern affects centrally and nationally authorised products and requires Union-level consideration without the statutory circumstances for Article 107i. Article 31 pharmacovigilance may be the appropriate mechanism.

Suppose the regulatory situation meets the statutory urgent-action criteria. Article 107i may apply.

The same scientific concern can therefore lead to different legal pathways depending on the regulatory facts surrounding it.

26. The Referral as a Transition Between Two Systems

The most useful conceptual distinction in this article is that a referral sits at the boundary between two related systems.

The first is the pharmacovigilance system, which continuously collects and evaluates evidence.

The second is the regulatory decision-making system, which determines whether the authorised conditions of a medicine should change.

The transition can be represented as:

PHARMACOVIGILANCE SYSTEM

Safety information
      ↓
Signal detection / monitoring
      ↓
Signal evaluation
      ↓
Medical assessment
      ↓
Benefit-risk consideration
      ↓
Regulatory escalation

                ↓
        FORMAL REFERRAL
                ↓

REGULATORY ASSESSMENT SYSTEM

Legal basis
      ↓
Defined scope
      ↓
Formal questions
      ↓
PRAC / CHMP assessment
      ↓
Scientific recommendation or opinion
      ↓
Union decision / position
      ↓
Implementation
      ↓
Continued pharmacovigilance

The systems are not separate in practice. They are connected through the evidence, governance and regulatory consequences of the safety issue.

For the QPPV, maintaining that connection is one of the central governance challenges of a major referral.

27. Practical Checklist for the First 48 Hours

The precise timetable varies by procedure, so this is an operational checklist rather than a statutory timeline.

Once the organisation becomes aware that a formal safety referral has started, it should rapidly establish:

1. Legal basis — Article 20, Article 31 or Article 107i.
2. Procedure status — formal initiation confirmed, not merely an emerging concern.
3. Products in scope — including authorisation routes.
4. Formal questions — exact wording and regulatory objective.
5. Published documents — notification, product list, questions and timetable.
6. Internal governance — accountable regulatory, safety, medical and quality functions as appropriate.
7. Evidence inventory — cases, exposure, studies, literature, previous assessments and risk-management information.
8. Data cut-off — establish which data are included and how subsequent information will be handled.
9. Submission route — confirm the current EMA requirements.
10. Communication control — establish a single authoritative internal position.
11. QPPV oversight — ensure the referral remains connected to the pharmacovigilance system.
12. Implementation planning — consider possible outcomes without assuming the final conclusion.

The phrase “first 48 hours” is deliberately operational rather than regulatory. There is no universal statutory 48-hour referral-response requirement. The applicable procedure-specific timetable controls the actual deadlines. EMA maintains separate current timetables for the relevant referral types. citeturn0search0

28. What the Next Stage Looks Like

Once the referral has been formally initiated and the MAH has entered the assessment phase, the central question changes.

The question is no longer:

“Should this safety issue be referred?”

It becomes:

“What does the evidence show, how should the evidence be interpreted, and what regulatory action is justified?”

That is the point at which PRAC's scientific assessment becomes central.

The next article in this series therefore moves inside the committee process and examines how PRAC assesses a safety issue during an EMA referral. It will address the role of rapporteurs, assessment reports, questions to the MAH, scientific uncertainty, benefit-risk assessment, risk-minimisation considerations and the transition from evidence assessment to the PRAC recommendation.

14. Common Misconceptions About Referral Initiation

Several recurring misunderstandings can lead to poor regulatory interpretation.

A safety signal does not equal a referral

Signal detection is an essential pharmacovigilance activity, but a signal can be handled in many ways without a Union referral. The existence of a signal does not predict the regulatory outcome.

A referral does not mean that the risk has been established

The referral is the formal mechanism through which the regulatory question is assessed. The scientific conclusion is developed during the procedure.

EMA does not independently decide that every important safety issue becomes a referral

The legal basis determines who can initiate the procedure. EMA has important scientific and coordination functions, but the formal initiation mechanism depends on the applicable legislation.

An MAH cannot simply choose the legal basis

The company may identify a need for Union action and, where legislation permits, initiate a particular procedure. It cannot simply label a concern as Article 20, Article 31 or Article 107i. The legal criteria determine the route.

Urgent does not mean scientifically unassessed

An Article 107i procedure addresses circumstances requiring urgent regulatory consideration. It does not eliminate the need for scientific assessment or permit conclusions unsupported by the available evidence.

Publication is not the regulatory outcome

The initial referral announcement establishes that a procedure has begun. It should not be read as equivalent to a PRAC recommendation, CHMP opinion, CMDh position or European Commission decision.

15. Inspection and Compliance Considerations

A referral can expose the quality of an MAH's pharmacovigilance system because the company must reconstruct its evidence base and demonstrate how the safety issue was recognised, evaluated and governed.

An inspection or regulatory review may reasonably examine whether the MAH can demonstrate a coherent history of the issue. Relevant records can include signal evaluations, case-series analyses, aggregate safety assessments, literature evaluations, epidemiological analyses, safety governance records, regulatory correspondence and decision-making documentation.

The important principle is contemporaneous traceability.

The company should be able to explain:

1. when the relevant information became available;
2. how it entered the pharmacovigilance system;
3. how it was assessed;
4. what conclusions were reached at each stage;
5. why particular regulatory actions were or were not taken;
6. how the issue was escalated internally;
7. how regulatory communications were controlled; and
8. how the organisation responded once the formal referral began.

A referral response should not be the first time that the company attempts to reconstruct the history of a safety concern.

QPPV perspective

The QPPV should be able to understand the relationship between the referral and the pharmacovigilance system as a whole. This includes knowing whether the issue was previously identified, how it was assessed, whether relevant safety activities were completed appropriately, and whether the referral has implications for the ongoing pharmacovigilance system.

The QPPV should also distinguish scientific disagreement from system failure. A signal can be assessed appropriately and still lead to a different regulatory conclusion later when additional evidence becomes available. A changed regulatory conclusion does not by itself demonstrate that the earlier pharmacovigilance assessment was deficient.

The inspection question is therefore not simply whether the company predicted the eventual regulatory outcome. It is whether the company had an adequate system, applied appropriate scientific judgement and maintained an auditable decision trail.

16. The MAH's Practical Response Once a Referral Is Initiated

Once the formal procedure starts, the organisation should move from ordinary signal-management governance to referral-specific programme governance without disconnecting the two.

A practical internal structure normally needs clear ownership for:

• regulatory strategy;
• pharmacovigilance assessment;
• medical review;
• epidemiology and biostatistics where relevant;
• clinical or non-clinical evidence assessment where relevant;
• regulatory writing;
• product-information assessment;
• risk-management assessment;
• legal review where necessary;
• submission operations;
• translation and implementation planning where applicable; and
• senior governance and decision-making.

The exact organisational model is a company matter. EU legislation does not prescribe a universal corporate referral team.

What matters from a compliance perspective is that responsibilities are clear and the response is controlled.

Establish the regulatory question before assembling the answer

One of the most common inefficiencies is to begin by collecting everything known about the safety issue.

The better starting point is the formal question.

The team should identify:

What exactly has the competent authority or Union body asked the committee to determine?

Only then should the evidence be mapped against that question.

This prevents a response from becoming a chronological data dump and makes it easier to distinguish evidence that directly addresses the regulatory question from information that is merely background.

Preserve the distinction between facts and interpretation

A strong referral response separates:

• observed facts;
• calculated results;
• methodological assumptions;
• scientific interpretation;
• uncertainty;
• company conclusions; and
• proposed regulatory actions.

This is especially important when evidence is conflicting.

A company should not describe a scientific interpretation as an established fact simply because it supports the preferred regulatory outcome.

17. A Worked Example: From Signal to Referral

Consider a hypothetical medicine authorised through both centralised and national routes.

A new pattern of serious hepatic events begins to appear in post-authorisation data. Initially, the MAH evaluates individual cases and aggregate information through its normal pharmacovigilance processes.

The evidence is insufficient to establish causality, but the pattern is sufficiently unusual to warrant further investigation.

The company performs additional analyses and reviews the literature and available epidemiological evidence. The issue is escalated through its safety governance structure.

At this stage, several outcomes remain possible:

• continued monitoring;
• additional risk-minimisation measures;
• a variation;
• a post-authorisation study or other additional pharmacovigilance activity; or
• Union-level referral.

Suppose further evidence indicates that the issue affects several products containing the active substance across different Member States. The regulatory question is no longer confined to one centrally authorised product.

The competent authorities therefore consider whether a Union procedure is appropriate and which legal basis applies.

If the circumstances do not meet the urgent criteria of Article 107i, an Article 31 pharmacovigilance referral may be appropriate where the interests of the Union are involved.

The important lesson is not the hypothetical choice itself. It is the sequence of reasoning:

Safety information
      ↓
Signal evaluation
      ↓
Accumulating evidence
      ↓
Regulatory concern
      ↓
Assessment of product and authorisation scope
      ↓
Assessment of urgency and applicable legal criteria
      ↓
Selection of legal mechanism
      ↓
Formal Union procedure

The legal mechanism is selected after the regulatory problem has been characterised, not simply because the underlying signal appears serious.

18. What the QPPV Should Be Able to Explain

If asked to explain why a safety referral was initiated, a QPPV should be able to describe the chain of reasoning without collapsing distinct stages into one statement.

A useful explanation has five layers.

Layer 1: Evidence

What information became available?

Layer 2: Pharmacovigilance assessment

What did the evidence indicate, and what uncertainty remained?

Layer 3: Regulatory significance

Why could the issue require a change to the authorised conditions, risk management or regulatory status?

Layer 4: Union significance

Why was a Union procedure relevant rather than management solely through an existing national or company mechanism?

Layer 5: Legal procedure

Why did the applicable facts and product scope correspond to the legal basis used to initiate the referral?

This layered explanation is more robust than saying simply that “PRAC wanted to review the safety issue.” PRAC's assessment follows the initiation of the relevant procedure; the legal framework determines how the matter reaches the committee.

19. A Practical Referral-Initiation Checklist

When a new potential referral is being discussed, a regulatory professional can work through the following questions:

This checklist is a working aid, not a substitute for the legislation or procedure-specific guidance.

20. Key Takeaways

A formal EMA safety referral is the endpoint of an initial regulatory escalation process, not the starting point of pharmacovigilance assessment.

The most important principles are:

1. Safety information is evaluated before a referral is considered.
2. A signal is a hypothesis requiring evaluation, not a confirmed adverse reaction or regulatory conclusion.
3. Most safety signals do not automatically become referrals.
4. The need for Union action depends on the regulatory problem, product scope, authorisation status, urgency and applicable legislation.
5. Article 20 pharmacovigilance concerns centrally authorised products.
6. Article 31 provides a Union-interest pharmacovigilance referral mechanism that can encompass nationally authorised and centrally authorised products within its scope.
7. Article 107i is a distinct urgent Union procedure with specific statutory circumstances.
8. The formal referral notification defines the regulatory frame for the assessment.
9. Referral initiation does not establish the safety risk or predetermine the regulatory outcome.
10. The MAH should organise its response around the formal regulatory question rather than simply reproducing the entire safety history.
11. The QPPV should be able to explain the connection between the safety concern, the pharmacovigilance assessment, the regulatory issue and the legal procedure.
12. A defensible referral response depends on contemporaneous, traceable evidence and clear separation of fact, analysis, uncertainty and regulatory interpretation.

The next stage is the scientific assessment itself. Once a referral has been formally initiated, PRAC must evaluate the evidence and determine what recommendation should follow. That process is examined in “How PRAC Assesses a Safety Issue During an EMA Referral.”

References

1. European Parliament and Council. Directive 2001/83/EC on the Community code relating to medicinal products for human use, as amended. EUR-Lex. The principal legal framework for nationally authorised medicinal products and the pharmacovigilance referral provisions relevant to Articles 31 and 107i.
2. European Parliament and Council. Regulation (EC) No 726/2004, as amended. EUR-Lex. The Union legal framework for centrally authorised medicinal products and the Article 20 procedure.
3. European Medicines Agency. Referral procedures for human medicines. EMA. Overview of referral mechanisms, initiation and committee pathways.
4. European Medicines Agency. Questions and answers: Article 20 pharmacovigilance procedures. EMA. Procedure-specific information for centrally authorised medicines.
5. European Medicines Agency. Questions and answers: Article 31 pharmacovigilance referrals. EMA. Procedure-specific information concerning Union-interest pharmacovigilance referrals.
6. European Medicines Agency. Questions and answers: Urgent Union procedures (Article 107i). EMA. Procedure-specific information concerning urgent Union pharmacovigilance procedures.
7. European Medicines Agency. Referral procedures: regulatory and procedural guidance. EMA. Current procedural guidance, including submission and timetable information.
8. European Medicines Agency. Procedural timetables for human medicines. EMA. Current timetable information for referral procedures, including Article 20/31 pharmacovigilance referrals and Article 107i urgent Union procedures.
9. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module IX — Signal Management. EMA. Guidance relevant to the identification, validation, analysis and management of safety signals.
10. European Medicines Agency. Good Pharmacovigilance Practices (GVP), Module V — Risk Management Systems. EMA. Guidance relevant to risk-management activities and the relationship between safety information and risk-management measures.

Regulatory Note

This article is an educational explanation of how a pharmacovigilance concern can progress into a formal EU referral. It is not a substitute for the applicable legislation, current EMA procedural guidance, national competent-authority requirements or the documents governing an individual referral.

The distinction between a safety signal, a safety concern, a regulatory issue and a formal referral is important. These terms describe different stages or concepts and should not be used interchangeably.

The legal basis must be established from the current applicable legislation and the facts of the individual case. In particular, the applicability of Articles 20, 31 and 107i depends on the statutory conditions, product scope, authorisation status and circumstances of the issue. This article does not create additional legal thresholds or procedural requirements.

The examples are hypothetical and are intended to illustrate regulatory reasoning. They do not represent actual referral determinations or imply that a particular set of facts necessarily requires a particular legal procedure.

EMA procedural guidance, legislation and procedural timetables can change. For an active referral or live regulatory decision, the current legal text, formal notification, procedure-specific timetable, questions referred, committee documents and legally operative regulatory outcome should be treated as controlling sources.

In particular, the initiation of a referral should never be interpreted as proof that a suspected risk has been confirmed or that a particular regulatory measure will necessarily follow. The scientific assessment and subsequent regulatory decision remain part of the procedure.